Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference
Aclarion (NASDAQ: ACON) announced its participation in the Selby Spine Conference, where Dr. Sigurd Berven will present the company's NOCISCAN platform. The presentation, titled 'MR Spectroscopy, Augmented Intelligence, and Low Back Pain – A New Gold Standard,' will showcase how NOCISCAN combines MR Spectroscopy with AI to help physicians identify biomarkers associated with disc pain that are invisible on traditional MRI scans.
NOCISCAN is the first evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine. This technology addresses a significant global healthcare challenge, as approximately 266 million people worldwide suffer from degenerative spine disease and low back pain. The presentation is scheduled for January 31, 2025, at 5:55 PM in Deer Valley, UT.
Aclarion (NASDAQ: ACON) ha annunciato la sua partecipazione al Selby Spine Conference, dove il Dr. Sigurd Berven presenterà la piattaforma NOCISCAN dell'azienda. La presentazione, intitolata 'Spettroscopia MR, Intelligenza Aumentata e Dolore Lombare – Un Nuovo Standard Oro,' mostrerà come NOCISCAN combini la spettroscopia MR con l'IA per aiutare i medici a identificare i biomarcatori associati al dolore discale che sono invisibili nelle scansioni MRI tradizionali.
NOCISCAN è la prima piattaforma SaaS supportata da evidenze che aiuta non invasivamente i medici a distinguere tra dischi dolorosi e non dolorosi nella colonna lombare. Questa tecnologia affronta una sfida significativa per la sanità globale, poiché circa 266 milioni di persone nel mondo soffrono di malattie degenerative della colonna vertebrale e dolore lombare. La presentazione è programmata per il 31 gennaio 2025, alle 17:55 a Deer Valley, UT.
Aclarion (NASDAQ: ACON) anunció su participación en la Selby Spine Conference, donde el Dr. Sigurd Berven presentará la plataforma NOCISCAN de la compañía. La presentación, titulada 'Espectroscopia por RM, Inteligencia Aumentada y Dolor Lumbar – Un Nuevo Estándar de Oro,' mostrará cómo NOCISCAN combina la espectroscopia por RM con IA para ayudar a los médicos a identificar biomarcadores asociados con el dolor discal que son invisibles en las exploraciones de RM tradicionales.
NOCISCAN es la primera plataforma SaaS respaldada por evidencias que ayuda de manera no invasiva a los médicos a distinguir entre discos dolorosos y no dolorosos en la columna lumbar. Esta tecnología aborda un desafío significativo en la salud global, ya que aproximadamente 266 millones de personas en todo el mundo padecen enfermedades degenerativas de la columna vertebral y dolor lumbar. La presentación está programada para el 31 de enero de 2025, a las 5:55 PM en Deer Valley, UT.
Aclarion (NASDAQ: ACON)은 Selby Spine Conference에 참여한다고 발표했으며, 여기서 Dr. Sigurd Berven이 회사의 NOCISCAN 플랫폼을 소개할 예정입니다. 'MR 분광학, 증강 지능, 그리고 요통 – 새로운 금 기준'이라는 제목의 발표에서는 NOCISCAN이 어떻게 MR 분광학을 인공지능과 결합하여 의사들이 전통적인 MRI 스캔에서 보이지 않는 디스크 통증과 관련된 바이오마커를 식별하는 데 도움을 주는지를 보여줍니다.
NOCISCAN은 비침습적으로 의사들이 요추에서 통증이 있는 디스크와 통증이 없는 디스크를 구별하는 데 도움을 주는 첫 번째 증거 기반 SaaS 플랫폼입니다. 이 기술은 전 세계적으로 약 2억 6천 6백만 명이 퇴행성 척추 질환과 요통으로 고통받고 있는 중요한 글로벌 건강 문제를 해결합니다. 발표는 2025년 1월 31일 오후 5시 55분에 유타주 디어 밸리에서 예정되어 있습니다.
Aclarion (NASDAQ: ACON) a annoncé sa participation à la Selby Spine Conference, où le Dr Sigurd Berven présentera la plateforme NOCISCAN de l'entreprise. La présentation, intitulée 'Spectroscopie par IRM, Intelligence Augmentée et Douleur Lombaire – Une Nouvelle Norme d'Or,' démontrera comment NOCISCAN combine la spectroscopie par IRM avec l'IA pour aider les médecins à identifier les biomarqueurs associés à la douleur discale qui sont invisibles sur les IRM traditionnelles.
NOCISCAN est la première plateforme SaaS soutenue par des preuves qui aide de manière non invasive les médecins à faire la distinction entre les disques douloureux et non douloureux dans la colonne lombaire. Cette technologie répond à un défi important de la santé mondiale, car environ 266 millions de personnes dans le monde souffrent de maladies dégénératives de la colonne vertébrale et de douleurs lombaires. La présentation est prévue pour le 31 janvier 2025, à 17h55 à Deer Valley, UT.
Aclarion (NASDAQ: ACON) gab seine Teilnahme an der Selby Spine Conference bekannt, wo Dr. Sigurd Berven die NOCISCAN-Plattform des Unternehmens präsentieren wird. Die Präsentation mit dem Titel 'MR-Spektroskopie, Augmentierte Intelligenz und Rückenschmerzen – Ein neuer Goldstandard' wird zeigen, wie NOCISCAN MR-Spektroskopie mit KI kombiniert, um Ärzten zu helfen, Biomarker zu identifizieren, die mit Bandscheibenschmerzen assoziiert sind und bei herkömmlichen MRI-Scans unsichtbar sind.
NOCISCAN ist die erste evidenzbasierte SaaS-Plattform, die Ärzten nicht-invasiv hilft, schmerzhafte von nicht schmerzhaften Bandscheiben in der Lendenwirbelsäule zu unterscheiden. Diese Technologie stellt eine bedeutende Herausforderung im globalen Gesundheitswesen dar, da weltweit etwa 266 Millionen Menschen an degenerativen Erkrankungen der Wirbelsäule und Rückenschmerzen leiden. Die Präsentation ist für den 31. Januar 2025, um 17:55 Uhr in Deer Valley, UT, geplant.
- First evidence-supported SaaS platform for noninvasive disc pain identification
- Addresses large market opportunity with 266 million potential patients worldwide
- Platform combines advanced MR Spectroscopy with AI technology
- None.
- Dr. Sigurd Berven to Highlight NOCISCAN Capabilities, Combining MR Spectroscopy and Augmented Intelligence (AI)
- NOCISCAN as New Gold Standard in Identifying a Source of Discogenic Pain
BROOMFIELD, Colo., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the Selby Spine Conference. Renowned spine specialist, Dr. Sigurd Berven, will present Aclarion's flagship platform, NOCISCAN, highlighting its innovative, evidence-supported capabilities.
“Aclarion is pleased to have NOCISCAN featured at the Shelby Spine Conference,” said Ryan Bond, Chief Strategy Officer. “We are honored to have renowned physicians like Dr. Berven illustrate how utilizing NOCISCAN can help physicians identify what they can’t ‘see’ with traditional imaging so they can personalize treatment for patients with chronic low back pain.”
Dr. Berven's presentation, titled "MR Spectroscopy, Augmented Intelligence, and Low Back Pain – A New Gold Standard," will delve into how NOCISCAN empowers physicians to noninvasively identify biomarkers that are invisible on traditional MRI scans. This breakthrough enables tailored, data-driven treatment plans for chronic low back pain patients.
Details of the Presentation:
- Date: Friday, January 31, 2025
- Time: 5:55 PM
- Location: Selby Spine Conference, Deer Valley, UT
NOCISCAN is revolutionizing spine surgery and chronic pain management by combining cutting-edge MR Spectroscopy with augmented intelligence, setting a new standard for noninvasive diagnostics.
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s NOCISCAN solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. NOCISCAN objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, NOCISCAN provides critical insights into the location of a patient’s low back pain.
For a copy of the NOCISCAN presentation, please email: info@aclarion.com
To find a NOCISCAN center, view our site map here.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with NOCISCAN, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, NOCISCAN receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, NOCISCAN provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contact:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
FAQ
What is Aclarion's NOCISCAN technology and how does it work?
When and where will Aclarion (ACON) present NOCISCAN at the Selby Spine Conference?
How many people could potentially benefit from Aclarion's NOCISCAN technology?
What advantage does NOCISCAN offer over traditional MRI scans?
